Last edition
News about "Hesham Abdullah"
Ris-Rez Cuts Risk of Death by 54 Percent vs Topotecan in Relapsed SCLC in China
Ris-Rez reduced the risk of death by 54 percent versus topotecan in relapsed SCLC in China, extending median overall survival to 18.5 months versus 10.3 months with comparator.
Hesham Abdullah | 15/09/2026 | By News Bureau
Hansoh Pharma Reports Positive Phase 3 Results for Ris-Rez in China
Hansoh Pharma reported positive phase 3 results for Ris-Rez in China, while GSK advances development across lung cancer, prostate cancer and other solid tumors.
Hesham Abdullah | 31/07/2026 | By News Bureau
GSK's Jemperli (dostarlimab) achieved durable complete responses in dMMR/MSI-H locally advanced rectal cancer, with potential to avoid chemotherapy, radiation, and surgery in some patients.
Hesham Abdullah | 14/07/2026 | By News Bureau | 122
GSK Reports Positive Data for B7-H4 ADC in Gynecological Cancers
GSK reports positive BEHOLD-1 data for B7-H4 ADC mocertatug rezetecan, showing strong response rates in ovarian and endometrial cancers, with Phase 3 trials planned.
Hesham Abdullah | 14/04/2026 | By News Bureau | 249
GSK and LTZ Collaborate to Advance Novel Myeloid Cell Engagers in Oncology
Leveraging LTZ’s novel immune-engager platform and GSK’s oncology expertise, the partnership aims to deliver potent, safer cancer therapies that can be administered in community settings, supporting GSK’s strategy to advance transformative medicines through cutting-edge technologies.
Hesham Abdullah | 20/11/2025 | By Dineshwori | 221
GSK Gains Exclusive Rights to Syndivia's Prostate Cancer ADC
GSK has obtained exclusive rights from Syndivia for a preclinical Antibody-Drug Conjugate (ADC) targeting metastatic Castration-Resistant Prostate Cancer (mCRPC), addressing an urgent need for novel therapies. The agreement expands GSK’s oncology pipeline with a potential best-in-class ADC designed to deliver enhanced anti-tumour activity.
Hesham Abdullah | 27/10/2025 | By Dineshwori | 389
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy